radium-223
Selected indexed studies
- Radium Ra 223 Dichloride. (, 2006) [PMID:32697462]
- Radium-223 for Metastatic Castrate-Resistant Prostate Cancer. (Pract Radiat Oncol, 2022) [PMID:35717046]
- Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial. (Ann Oncol, 2025) [PMID:40450503]
_Worker-drafted node — pending editorial review._
Connections
radium-223 is a side effect of
Sources
- Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial. (2025) pubmed
- Radium Ra 223 Dichloride. (2006) pubmed
- Radium-223 for Metastatic Castrate-Resistant Prostate Cancer. (2022) pubmed
- Radium-223 as an Approved Modality for Treatment of Bone Metastases. (2020) pubmed
- EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. (2018) pubmed
- Review of Radium-223 and Metastatic Castration-Sensitive Prostate Cancer. (2020) pubmed
- Radium-223 mechanism of action: implications for use in treatment combinations. (2019) pubmed
- Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. (2019) pubmed
- Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why. (2019) pubmed
- Radium-223 and bone metastatic disease: still more to learn. (2023) pubmed